Allergy Therapeutics PLC
LSE:AGY

Watchlist Manager
Allergy Therapeutics PLC Logo
Allergy Therapeutics PLC
LSE:AGY
Watchlist
Price: 5.1 GBX -1.92% Market Closed
Market Cap: 243.1m GBX
Have any thoughts about
Allergy Therapeutics PLC?
Write Note

Allergy Therapeutics PLC
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Allergy Therapeutics PLC
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Allergy Therapeutics PLC
LSE:AGY
Operating Income
-ÂŁ38.8m
CAGR 3-Years
N/A
CAGR 5-Years
-74%
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Operating Income
ÂŁ7.6B
CAGR 3-Years
2%
CAGR 5-Years
-2%
CAGR 10-Years
2%
AstraZeneca PLC
LSE:AZN
Operating Income
$10.3B
CAGR 3-Years
34%
CAGR 5-Years
19%
CAGR 10-Years
13%
Verona Pharma PLC
NASDAQ:VRNA
Operating Income
-$155.4m
CAGR 3-Years
-37%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Operating Income
$617m
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
3%
Dechra Pharmaceuticals PLC
LSE:DPH
Operating Income
ÂŁ24.9m
CAGR 3-Years
-25%
CAGR 5-Years
-11%
CAGR 10-Years
3%
No Stocks Found

Allergy Therapeutics PLC
Glance View

Market Cap
243.1m GBX
Industry
Pharmaceuticals

Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.

AGY Intrinsic Value
4.28 GBX
Overvaluation 16%
Intrinsic Value
Price

See Also

What is Allergy Therapeutics PLC's Operating Income?
Operating Income
-38.8m GBP

Based on the financial report for Dec 31, 2023, Allergy Therapeutics PLC's Operating Income amounts to -38.8m GBP.

What is Allergy Therapeutics PLC's Operating Income growth rate?
Operating Income CAGR 5Y
-74%

Over the last year, the Operating Income growth was -43%.

Back to Top